A unique case of very low‐dose subcutaneous ketamine use: Maintenance option of ketamine for treatment‐resistant depression
Adem T. Can, Daniel F. Hermens, Jim Lagopoulos
Clinical Case Reports December 1, 2022 DOI: 10.1002/ccr3.6675 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | Patient with severe treatment-resistant depression |
| Intervention | subcutaneous ketamine |
| Dose | very low-dose |
| Topics | Depression Esketamine Ketamine |
| Citations | 6 |
| Key findings | Very low-dose subcutaneous ketamine maintenance therapy sustained antidepressant response in a patient with severe treatment-resistant depression. |
Abstract
Abstract Numerous studies have demonstrated that low‐dose subanesthetic intravenous ketamine infusion treatment leads to rapid improvement of treatment‐resistant depression. The following case report describes the use of a very low‐dose subcutaneous ketamine as a form of maintenance in a patient with severe treatment‐resistant depression using a retrospective chart review.
Comparable studies
Other case reports and case series on ketamine for depression, most cited first.
Citations in the library
Cited by 2
- Ketamine in psychiatry: Ethical imperatives in harnessing a controversial yet promising therapy Australian & New Zealand Journal of Psychiatry December 11, 2025
- Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review. General Hospital Psychiatry 2026
Cites 7
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. American Journal of Psychiatry March 29, 2019
- Ketamine: 50 Years of Modulating the Mind Frontiers in Human Neuroscience November 29, 2016
- Subcutaneous Ketamine in Depression: A Systematic Review Frontiers in Psychiatry May 28, 2021
- The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? Pharmacology & Therapeutics October 2018
and 2 more in the library